AcuityMD Raises $80 Million Series C at Reported $955 Million Valuation

According to a recent LinkedIn post from AcuityMD, the company has raised $80 million in Series C financing, led by StepStone Group with participation from Benchmark, Redpoint, ICONIQ, and Atreides Management. The post indicates this brings total funding to more than $160 million and implies a valuation of $955 million.

The LinkedIn post also notes that close to 500 MedTech companies, including 16 of the top 20, are described as using AcuityMD’s platform. This customer traction, if sustained, could support revenue growth, enhance recurring software economics, and strengthen the company’s competitive position in the medical technology commercialization software segment.

According to the post, new capital is expected to support three focus areas: advancing “agentic AI” tools for commercial teams, deepening the data ontology underpinning AcuityMD, and expanding offerings beyond commercial workflows to cover the broader MedTech product lifecycle. These initiatives suggest an effort to increase product breadth and data differentiation, which may improve pricing power and customer lock-in over time.

The emphasis on integrating disparate datasets such as claims databases, FDA filings, and government records highlights a data-aggregation strategy that could create high barriers to entry for competitors. For investors, the nearly $1 billion valuation and backing from well-known growth investors may signal expectations of continued rapid scaling in a complex but sizable MedTech market, though execution risk around AI development and lifecycle expansion remains a key variable.